H3 Health Hub’s Post

🔬 Don't miss the Early-Stage Therapeutics panel at RESI Boston 2024! 💊 Join industry leaders as they discuss: • Decision-making processes for biotech investments • Hot areas in therapeutics • Standing out in crowded markets • Common pitfalls to avoid • Recent success stories Gain invaluable insights on sourcing novel assets, emerging technologies, and navigating the path to commercialization. Featured panelists: • Ashim Subedee - Division of Research Innovation and Ventures • Chris Garabedian - Xontogeny • Jill Goldstein - Vida Ventures, LLC • Squire Severance - Syridex Bio • Claire Leurent PhD MBA - AbbVie Ventures • Allan Gobbs - ATEM Capital Register now for RESI Boston (September 25-27) to connect with these experts and other early-stage investors: https://lnkd.in/e7QS-AZi Don't miss this opportunity to accelerate your biotech startup's growth! #RESIBoston #Biotech #Therapeutics #Investing #StartupGrowth #VentureCapital #Pharma #Innovation #EarlyStageInvesting #Networking

Foresite Capital Launches $900M Biotech Fund Foresite Capital, under the leadership of Jim Tananbaum, M.D., has gathered a staggering $900 million for their latest fund, signaling a bullish stance in what is considered one of the top investment environments for biotech. Since its inception in 2011, Foresite has played a significant role in propelling innovation at the nexus of technology and biology. Their sixth fund is set to escalate advancements in precision therapeutics, life science technologies, and healthcare systems. Portfolio companies such as Alumis, Latigo Biotherapeutics, and Xaira Therapeutics have experienced substantial funding rounds, ranging from $135M to $1B, despite the overall contraction in investment flows. With a robust track record of 47 IPOs, noteworthy acquisitions, and 58 FDA approvals for novel medicines, Foresite's strategies are proven to foster monumental health sector breakthroughs. Jim Tananbaum envisions the fusion of biology, genomics, and AI initiating a transformative chapter for patient care and investor revenue. #BiotechInvestment #PrecisionTherapeutics #HealthcareInnovation

Enveda Biosciences Secures $55M to Advance AI-Driven Drug Discovery - Major Funding Round: Enveda Biosciences, a biotech firm specializing in AI-driven drug discovery, raised $55M in a Series B2 round, bringing total funding to $230M. - Strategic Investors: New investors include Premji Invest, Lingotto Investment Fund, Microsoft, and The Nature Conservancy, with continued support from existing backers. - Advancing Drug Development: Funds will enhance Enveda’s AI platform and support Phase I clinical trials for three lead programs, including a novel treatment for atopic dermatitis. Subscribe to our daily newsletter here for more AI news https://lnkd.in/d_cKz6EH #AI #Healthcare #Innovation #Technology #Future #Startups #Entrepreneurship #VentureCapital #ArtificialIntelligence #DigitalMarketing

Let Venture Capital Firms and NUVISAN Boost Your Drug Discovery Project! Are you working on an orphan disease drug discovery project or tackling challenging targets? This is your opportunity to collaborate with venture capitalists and scientific experts to propel your drug discovery initiative forward. The 2nd NUVISAN Innovation Challenge is seeking groundbreaking ideas in this space to accelerate the development of new treatments for patients in need. 🎯 Theme: Innovative Solutions for Orphan Diseases and Challenging Drug Targets 🎁 Prizes: Winners will have the opportunity to present their ideas to venture capitalists and receive expert scientific consultation from NUVISAN. 🌐 Who Can Apply: Companies worldwide working to address these unmet needs are encouraged to participate. 📅 Submission Deadline: October 29 Explore the event details here: https://lnkd.in/e7skKGDP We look forward to your application! #NUVISAN #ScienceCRO #InnovationChallenge #DrugDiscovery #OrphanDrugs #Biotech #VentureCapital

On 6 June we hosted our 2nd annual life sciences conference in London. Some of the leading names from venture capital, private equity, pharma, biotech and academia came together to tackle some of the challenging, and exciting topics facing the sector today. Highlights included a panel on the sector's funding landscape with differing 'contrarian' views, and our keynote’s emphasis on the potential that can be unlocked in Europe through cooperation and collaboration. #privatemarkets #assetmanagement #realestate #lifesciences #alternatives #venturecapital #biotech #AI

Integrated Biosciences Secures $17.2 Million to Develop Medicines for Age-Related Diseases Integrated Biosciences, Inc., a California-based biotechnology startup pioneering medicines targeting age-related illnesses, has secured $17.2 million in seed funding to advance treatment for healthier aging. Co-founded in September 2022 by Felix Wong and Max Wilson, the company develops cellular rejuvenation therapies using a combination of small molecules and optogenetics. The seed round was backed by a consortium of companies spearheaded by Sutter Hill Ventures, with significant contributions from notable investors, including Root Ventures, llumina Ventures Labs, Civilization Ventures, Lifespan Vision Ventures, SH funds (Sabrina Hahn), Overlap Holdings, Conscience VC, Reinforced Ventures, Mission BioCapital, Polymath Capital, Vijay Pandurangan and Michael Stoppelman. Read more: https://lnkd.in/gWHvZu5M #fundingnews #FundingOpportunity #StartupFunding #StartupSuccess #HealthcareNews #Biotechnology #HealthcareFunding #nextdigitalhealth #Wi4 #vineetagrawal

At Clora, we’re dedicated to fostering innovation and collaboration within the biotech community. That’s why we’re thrilled to share highlights from the recent Bio-IT World Conference where our Founder & CEO, Rahul Chaturvedi moderated an insightful panel discussion on “Strategies for Biotech Success: Insights on Raising Capital from CEOs and VCs.” In an ever-evolving landscape, navigating capital acquisition is paramount for biotech companies. Rahul led the discussion, delving into recent shifts in funding trends, anticipating market expectations, and providing invaluable and actionable insights on selecting the right investors amidst competitive markets. Missed the discussion? Reach out / comment below ⬇ to learn more about how Clora is driving innovation and collaboration in the biotech landscape. 🌟 Many thanks to the amazing panelists - Kimberly Nearing from BVCF Management Ltd, Trevor Perry from Selas Ventures, Jami Rubin from Boundless Bio and ARCH Venture Partners, Chris Shibutani MD MBA from Goldman Sachs, and Scott Megaffin from Adiso Therapeutics. 🌟 #Biotech #BioITWorld #Clora #VC

💰BIO Roundup: Deal-Making Tips And Tricks • WHO SHOULD READ THIS? BD&L professionals in small companies looking for larger partners or investors. • WHAT IS IT? A round-up of insights gathered by Citeline News & Insights reporters from panel discussions and in exclusive interviews at the BIO International Conference on the subject of deal-making. • WHY IS IT IMPORTANT? Biotech companies are competing for the attention of potential partners to fund their R&D and help them achieve commercial success. This feature highlights key advice on decision-making, ranging from pipeline strategy to approaching international markets. Citeline Citeline Commercial #BIO2024

Regeneron steps up! With the launch of Regeneron Ventures and a commitment of $100 million annually for five years, this landmark move can help revitalize the biotech startup ecosystem. The initiative could provide crucial support and open new opportunities for those affected by recent layoffs and shutdowns in the sector. Here's to empowering #entrepreneurs to bring innovative therapies from concept to patient care. #Biotech #VentureCapital #Innovation

On 6 June we hosted our 2nd annual life sciences conference in London. Some of the leading names from venture capital, private equity, pharma, biotech and academia came together to tackle some of the challenging, and exciting topics facing the sector today. Highlights included a panel on the sector's funding landscape with differing 'contrarian' views, and our keynote’s emphasis on the potential that can be unlocked in Europe through cooperation and collaboration. #privatemarkets #assetmanagement #realestate #lifesciences #alternatives #venturecapital #biotech #AI